Single-Layer NAKET Tablet for Steady Oral Ketamine Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral ketamine formulations face challenges with short therapeutic windows and neurologically toxic plasma concentration spikes, necessitating frequent administration and increased side effects, limiting their effectiveness in treating conditions like pain, depression, and brain injury.
Innovation Solution
Development of single-layer oral neuro-attenuating ketamine (NAKET) tablets using a combination of water-insoluble neutrally charged non-ionic matrices and polymers with negatively charged groups to achieve steady ketamine release without psychotomimetic toxic spikes, providing therapeutic efficacy for up to 24-36 hours post-administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral ketamine formulations are administered to achieve therapeutic effects, then pain relief and other therapeutic benefits are improved, but neurologically toxic plasma concentration spikes occur causing sedation, hallucination, dizziness, and nausea
Solution Approach 1:
The patent segments the single oral dose into controlled-release formulations that deliver ketamine gradually over time, preventing toxic plasma concentration spikes while maintaining therapeutic efficacy. The segmented delivery system divides the drug release into manageable phases that avoid overwhelming the neurological system.
Solution Approach 2:
The patent implements periodic action through controlled-release mechanisms that administer ketamine at regulated intervals and rates. This periodic delivery pattern maintains plasma concentrations within the therapeutic window (10-300 ng/ml) without exceeding into toxic ranges, thereby preventing neurological side effects while sustaining therapeutic benefits.
2Reliability
If multiple daily doses of oral ketamine are administered to maintain therapeutic effect, then therapeutic coverage is improved, but treatment compliance deteriorates due to frequent administration requirements
Solution Approach 1:
The patent implements continuity of useful action through extended-release formulations that maintain therapeutic ketamine levels continuously over 24 hours or longer with a single administration. This continuous delivery eliminates the need for multiple daily doses while sustaining therapeutic coverage, thereby significantly improving treatment compliance and patient convenience.
3Object-affected harmful factors
If infusion administration is used to maintain stable drug levels over longer periods, then neurological side effects are eliminated, but device complexity and administration difficulty increase requiring ICU settings
Solution Approach 1:
The patent extracts the complex infusion delivery system and replaces it with a simplified oral tablet formulation that inherently provides controlled-release functionality. By taking out the need for infusion pumps, monitoring equipment, and ICU infrastructure, the invention delivers similar therapeutic outcomes through a simple oral administration that patients can self-administer at home.
Solution Approach 2:
The patent introduces a controlled-release matrix or delivery system as an intermediary between the oral ketamine dose and the patient's bloodstream. This intermediary mechanism regulates drug release kinetics, mimicking the stable plasma levels achieved through infusion without requiring the complex infusion apparatus, thereby simplifying administration while maintaining safety.
4Ease of operation
If solid dose forms of ketamine are administered to provide convenient oral delivery, then ease of administration is improved, but the ability to provide therapeutically effective doses without toxic spikes deteriorates
Solution Approach 1:
The patent employs composite materials in the form of controlled-release matrices, polymers, or formulation systems that combine ketamine with release-modifying excipients. These composite structures enable the solid oral dose to release ketamine gradually, maintaining safe plasma concentrations while providing therapeutically effective dosing, thus resolving the contradiction between convenience and safety.
Data Source
AI summary
The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.